APA (7th ed.) Citation

Fischer, S., Donhauser, M., Cohnen, S., Fietkau, K., Vetter, M., Grübel-Liehr, M., . . . Atreya, R. Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: Results of a prospective long-term cohort study. SAGE Publishing.

Chicago Style (17th ed.) Citation

Fischer, Sarah, et al. Reverse Switching from the Biosimilar SB2 to the Originator Infliximab in Previously Switched Patients with Inflammatory Bowel Diseases: Results of a Prospective Long-term Cohort Study. SAGE Publishing.

MLA (9th ed.) Citation

Fischer, Sarah, et al. Reverse Switching from the Biosimilar SB2 to the Originator Infliximab in Previously Switched Patients with Inflammatory Bowel Diseases: Results of a Prospective Long-term Cohort Study. SAGE Publishing.